NextCure, Inc. (NASDAQ:NXTC) is among the top gainers of the stock market today, skyrocketing 4.71% or (2.06 points) to $45.65 from its previous close of $43.59. Does this growth mean it the best stock to buy right now? The shares seem to have an active trading volume day with a reported 238868 contracts so far this session. NXTC shares had a relatively better volume day versus average trading capacity of 456.49 thousand shares, but with a 22.96 million float and a 18.42% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for NXTC stock indicates that the average analyst price target is $72.25 per share. This means the stock has a potential increase of 58.27% from where the NXTC share price has been trading recently which is between $42.7 and $48.8599.
Looking at the current readings for NextCure, Inc., the two-week RSI stands at 54.18. This figure suggests that NXTC stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current NXTC readings is similarly very revealing as it has a stochastic reading of 77.34% at this stage. This figure means that NXTC share price today is being oversold.
Technical chart claims that NextCure, Inc. (NXTC) would settle between $47.4/share to $51.21/share level. However, if the stock price goes below the $41.24 mark, then the market for NextCure, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $38.89 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 4.95. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at BTIG Research, assumed coverage of NXTC assigning Buy rating, according to their opinion released on November 26. BofA/Merrill, analysts launched coverage of NextCure, Inc. (NASDAQ:NXTC) stock with a Buy recommendation, according to their flash note issued to investors on July 09. Analysts at Piper Jaffray, made their first call for the equity with a Overweight recommendation, according to a research note that dated back to June 03.
NXTC equity has an average rating of 2, with the figure leaning towards a bullish end. 2 analysts who tracked the company were contacted by Reuters. Amongst them, 0 rated the stock as a hold while the remaining 2 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 2 analysts rated NextCure, Inc. (NASDAQ:NXTC) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.